Drug details

Repatha (evolocumab injection, for subcutaneous injection)

type of PCSK9 Inhibitors

Repatha (evolocumab) Injection is a human monoclonal immunoglobulin G2 (IgG2) as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C). Repatha is also indicated as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C.

This drug may have the following side effects:

• headache,
• dizziness,
• cough,
• runny or stuffy nose,
• diarrhea, and
• back pain,
• muscle pain,
• urinary tract infection,
• sinus infection,
• upper respiratory tract infection,
• high blood pressure,
• influenza,
• injection site reactions (redness, pain, and bruising),
• allergic reactions (rash and hives),
• stomach upset.

The following drugs are related to Repatha, either as a replacement or used together:

• Advicor (niacin xr and lovastatin)
• Praluent (alirocumab for solution for subcutaneous injection)
• Altoprev (lovastatin extended-release tablets)
• Caduet (amlodipine besylate, atorvastatin calcium)
• Nexlizet (bempedoic acid and ezetimibe tablets)
• Evkeeza (evinacumab-dgn for injection)
• Vytorin (ezetimibe and simvastatin)
• Zetia (ezetimibe tablets)
• Fenofibrate 40 mg/ 120 mg (fenofibrate)
• Lescol (fluvastatin sodium)
• Leqvio (inclisiran injection)
• Livalo (pitavastatin)
• Rosuvastatin Calcium Tablets (rosuvastatin calcium)